Vestal Point Capital, LP Taysha Gene Therapies, Inc. Transaction History
Vestal Point Capital, LP
- $1.9 Trillion
- Q2 2025
A detailed history of Vestal Point Capital, LP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 3,000,000 shares of TSHA stock, worth $15 Million. This represents 0.36% of its overall portfolio holdings.
Number of Shares
3,000,000Holding current value
$15 Million% of portfolio
0.36%Shares
1 transactions
Others Institutions Holding TSHA
# of Institutions
155Shares Held
244MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$125 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$118 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$109 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$84.3 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY12.6MShares$63 Million11.04% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $242M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...